US Pharma MarketingMironid banks $46m in Series B to take rare kidney disease drug closer to clinic
Mironid banks $46m in Series B to take rare kidney disease drug closer to clinic is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
This funding round will set Mironid up until the generation of initial clinical data, the company’s CEO says.
Source: Pharmaceutical Technology